Don’t miss – Page 16 – Endpoints News

SUBSCRIBE

AstraZeneca challenges Roche on frontline SCLC after seizing an interim win — and Merck may not be far behind

5 months ago

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

5 months ago

After raising $158M, this upstart's founders have star backers and plans to break new ground in gene therapy

5 months ago

AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash

5 months ago

AbbVie seals $63B deal to buy a troubled Allergan — spelling out $1B in R&D cuts

5 months ago

In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later

5 months ago

Why would the FDA approve another controversial drug to spur a woman’s libido with these data? And why no expert panel review?

5 months ago

Which top 10 big pharmas have the most to gain — or lose — over the next 5 years?

5 months ago

HIV, pneumococcal — and what? Merck's unexpected pipeline highlight excites a little biotech

5 months ago

Who’s next in line to succeed Ken Frazier as CEO of the Keytruda-blessed Merck?

5 months ago

Sanofi's John Reed continues to reorganize R&D, cutting 466 jobs while boosting cancer, gene therapy research

5 months ago

A new number 1 drug? Keytruda tapped to top the 10 biggest blockbusters on the world stage by 2024

5 months ago

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

5 months ago

After watching its share price soar on a Bloomberg report and heated rumors, Biohaven stock takes a billion-dollar bath

5 months ago

The top 10 blockbuster drugs in the late-stage pipeline — Evaluate adds 6 new therapies to heavy-hitter list

5 months ago

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

5 months ago

Pfizer CEO Albert Bourla is back in the M&A game, but why is he paying $11.4B for Array?

5 months ago

Global Blood Therapeutics poised to submit application for accelerated approval, with new pivotal data on its sickle cell disease drug

5 months ago

Gene therapies seize the top of the list of the most expensive drugs on the planet — and that trend has just begun

5 months ago

As another antibiotics biotech sinks into a crisis, warnings of a sector ‘collapse’

5 months ago

Bain’s biotech team has created a $1B-plus fund — with an eye to more Big Pharma spinouts

6 months ago

Searching for the next blockbuster to follow Darzalex, J&J finds a $150M anti-CD38 drug from partner Genmab

6 months ago

Merck makes a $773M bet on TGFβ, acquiring a three-year-old biotech

6 months ago

As investor confidence crumbles following fund suspension, Neil Woodford faces backlash on fees

6 months ago

First page Previous page 13 14 151617 18 19 Next page Last page